Pfizer logo is reflected in a drop on a syringe needle in this illustration photo taken March 16, 2021. Picture taken March 16, 2021. REUTERS/Dado Ruvic/Illustration
| Pfizer Inc (PFE.N) has submitted data on its COVID-19 vaccine among 12- to 15-year-olds to Britain's health regulator, according to a company spokesman on Tuesday, paving the way for the company to be authorised to inoculate children in the country.
"I can confirm we've submitted data on the efficacy of the vaccine in 12 to 15-year-olds for review by the U.K. MHRA," the spokesman said via email to Reuters.
The announcement comes just one day after US regulators approved the vaccine developed by Pfizer and BioNTech SE (22UAy.DE) for use in children as young as 12 years old.
Pfizer and BioNTech announced in March that their COVID-19 vaccine was safe, effective, and produced robust antibody responses in 12- to 15-year-olds, citing a trial of 2,260 adolescents that showed 100% efficacy in preventing the illness. more info
Pfizer has stated that it expects to have safety and efficacy data on the vaccine for children aged 2 to 11 by September, when it intends to request that age group be included in the emergency authorization.
The Telegraph previously reported that Pfizer had requested approval for the vaccine from the UK's Medicines and Healthcare products Regulatory Agency. | 
|
Use left/right arrows to navigate the slideshow or swipe left/right if using a mobile device
